The Medical Letter on Drugs and Therapeutics
Transdermal Selegiline (Emsam)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA recently approved the monoamine oxidase inhibitor (MAOI) selegiline in a transdermal (patch) formulation (Emsam – Bristol-Myers Squibb/Somerset) for treatment of major depressive disorder. Selegiline is also available in an oral formulation (Eldepryl, and others) for treatment of Parkinson’s disease.1

MAOIs — MAOIs are highly effective for treatment of depression, including some cases resistant to selective serotonin reuptake inhibitors (SSRIs) and other drugs.2 The mechanism of action of MAOIs in depression is not completely understood, but they are involved in catabolism of serotonin, norepinephrine and dopamine in the brain. Older MAOIs such as phenelzine (Nardil), tranylcypromine (Parnate) and isocarboxazid (Marplan) are nonselective and inhibit both the A and B subtypes of MAO. Blocking MAO-A in the GI tract ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Transdermal Selegiline (Emsam)
Article code: 1235a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian